The ZC 25 imprint identifies a prescription oral tablet containing Meloxicam 7.5 mg. Manufactured by Zydus Pharmaceuticals, meloxicam belongs to the nonsteroidal anti-inflammatory drug (NSAID) class and is primarily used to relieve joint pain, swelling, and stiffness caused by arthritis.
Physical Identification
Physical Parameter – Specification
- Active Ingredient – Meloxicam (7.5 mg)
- Form – Solid oral tablet
- Shape – Round
- Color – Yellow (or pale yellow)
- Size – 6 mm diameter
- Imprint – ZC 25 debossed on one side, plain on the reverse
- Manufacturer – Zydus Pharmaceuticals
- Drug Class – Nonsteroidal Anti-Inflammatory Drug (NSAID)
- CSA Schedule – Non-Controlled (Prescription Only)
- If you hold a yellow round pill with the imprint ZC 26, that is the higher 15 mg strength of meloxicam. Always verify unidentified medications with a pharmacist.
Mechanism of Action
Meloxicam works by inhibiting the cyclooxygenase (COX) enzymes responsible for converting arachidonic acid into pro-inflammatory prostaglandins.
- COX-2 Selectivity: At lower therapeutic doses (such as 7.5 mg), meloxicam exhibits relative selectivity for the COX-2 enzyme over the COX-1 enzyme.
- COX-2 Inhibition: Suppresses the production of inflammatory prostaglandins at joint sites, reducing swelling, fever, and pain hypersensitivity.
- COX-1 Relative Sparing: COX-1 is involved in maintaining gastrointestinal mucosal linings and platelet aggregation. Relative COX-2 selectivity aims to offer anti-inflammatory power with lower baseline gastrointestinal toxicity compared to traditional non-selective NSAIDs (like ibuprofen or indomethacin).
- High Dose Behavior: At higher doses (such as 15 mg daily), meloxicam loses much of its COX-2 selectivity and inhibits COX-1 to a greater degree.
Indications & Approved Usage
Meloxicam 7.5 mg is FDA-approved for the management of pain and inflammation in:
- Osteoarthritis (OA): Relief of signs and symptoms of degenerative joint disease in adults.
- Rheumatoid Arthritis (RA): Long-term management of chronic inflammatory joint disease in adults.
- Juvenile Rheumatoid Arthritis (JRA): Relief of symptoms in pediatric patients aged 2 years and older weighing (dosage titrated by weight).
Dosage Guidance
- Core Principle: Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals to minimize cardiovascular and gastrointestinal risks.
Adults (Osteoarthritis & Rheumatoid Arthritis)
- Starting Dose: 7.5 mg taken orally once daily with or without food.
- Maximum Dose: May be increased to 15 mg once daily for patients who require additional symptom relief. The maximum recommended daily limit is 15 mg per day.
- Administration Tip: Taking meloxicam with meals or milk can help minimize mild stomach upset.
Patients on Hemodialysis
In patients with end-stage renal disease (ESRD) undergoing hemodialysis, the maximum daily dose should not exceed 7.5 mg daily.
Side Effects
Common Side Effects
- Gastrointestinal: Dyspepsia (indigestion), abdominal pain, nausea, diarrhea, and flatulence.
- Central Nervous System: Dizziness, headache, or mild fatigue.
- Respiratory/General: Upper respiratory tract infections, sore throat, or mild swelling of the lower legs (peripheral edema).
Severe Adverse Reactions
Seek immediate medical attention if any of the following occur:
- Gastrointestinal Bleeding: Black/tarry stools, vomiting material that looks like coffee grounds, or severe stomach pain.
- Severe Skin Reactions: Blistering skin, fever, or rash (e.g., Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis).
- Hepatotoxicity: Jaundice (yellowing of skin/eyes), dark urine, upper right quadrant pain, or severe flu-like fatigue.
- Renal Toxicity: Unexplained weight gain, swelling, or sudden reduction in urine production.
Precautions & Boxed Warnings
FDA Boxed Warnings (Black Box)
Cardiovascular Risk:
- NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk can occur early in treatment and increases with higher doses and longer duration of use.
- Meloxicam is strictly contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Gastrointestinal Risk:
- NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
- Elderly patients and those with a history of peptic ulcer disease or GI bleeding are at the greatest risk.
Important Warnings & Contraindications
- Aspirin-Sensitive Asthma: Do not take meloxicam if you have a history of asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs (risk of severe, fatal anaphylaxis).
- Pregnancy Warning (20 Weeks and Later): Avoid use of NSAIDs starting at 20 weeks of gestation as it can cause premature closure of the fetal ductus arteriosus and lead to fetal renal dysfunction resulting in oligohydramnios (low amniotic fluid).
- Renal Function: Not recommended in patients with severe, uncompensated renal impairment without close monitoring.
- Hypertension: NSAIDs can cause onset of new hypertension or worsening of pre-existing high blood pressure.
Key Drug Interactions
- Anticoagulants & Antiplatelets (e.g., Warfarin, Aspirin, Clopidogrel): Concomitant use significantly increases the risk of serious GI bleeding.
- ACE Inhibitors, ARBs, & Diuretics: NSAIDs can diminish the antihypertensive effect of these drugs and increase the risk of severe acute renal impairment.
- Lithium & Methotrexate: Meloxicam inhibits renal clearance of lithium and methotrexate, leading to elevated toxicity levels.